Latest News

Circassia Achieves Positive Phase II Clinical Results With Ragweed Allergy T-cell Vaccine

Results Mark Third Successful Phase II Study With ToleroMune T-Cell Vaccines

12 February 2010

Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-cell Vaccines Against House Dust Mite and Cat Allergies

19 January 2010

Circassia Raises £15million ($25million) in Oversubscribed Investment Round

11 December 2009

Circassia announces successful results from phase II clinical study of ToleroMune cat allergy therapy

Study Identifies Optimal Treatment Approach For Late-Stage Development

20 November 2009

Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy

New ToleroMune treatment extends clinical-stage portfolio

13 May 2009

Previous news articles

Did you know?

The average bed could be home to up to 1.5 million house dust mites